A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Human Cytomegalovirus Protein Expression Is Correlated with Shorter Overall Survival in Breast Cancer Patients: A Cohort Study




TekijätTouma Joel, Pantalone Mattia Russel, Rahbar Afsar, Liu Yan, Vetvik Katja, Sauer Torill, Söderberg-Naucler Cecilia, Geisler Jürgen

KustantajaMDPI

Julkaisuvuosi2023

JournalViruses

Tietokannassa oleva lehden nimiVIRUSES-BASEL

Lehden akronyymiVIRUSES-BASEL

Artikkelin numero 732

Vuosikerta15

Numero3

Sivujen määrä13

DOIhttps://doi.org/10.3390/v15030732

Verkko-osoitehttps://www.mdpi.com/1999-4915/15/3/732

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/179339328


Tiivistelmä

Background: Human cytomegalovirus (HCMV) is increasingly suggested to be involved in human carcinogenesis and onco-modulation due to its ability to contribute to all hallmarks of cancer. Growing evidence demonstrates a link between HCMV infection and various malignancies, including breast cancer, which incidence and mortality are still on the rise. The etiology of breast cancer remains mostly unclear, leaving 80% of breast cancer cases considered to be sporadic. Identifying novel risk- and prognostic factors for improved breast cancer treatment and increased survival rates, were the objectives of this study.

Methods: Automated immunohistochemical staining results for HCMV proteins in 109 breast tumors and lymph node metastasis were correlated with clinical follow-up data (>10 years). Statistical analyses for median Overall Survival (OS) were performed.

Results: Survival analyses revealed shorter median OS for patients with HCMV-IE positive tumors of 118.4 months compared to 202.4 months for HCMV-IE negative tumors. A higher number of HCMV-LA positive cells in the tumors was also associated with a shorter OS in patients (146.2 months vs. 151.5 months).

Conclusions: Our findings suggest a link between HCMV-infections and breast cancer prognosis, which paves the way for potential novel clinical intervention and targeted therapy that may prolong the overall survival of selected patients with breast cancer.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 20:04